Trough concentration may not be a good target for polymyxin B therapeutic drug monitoring

Trough concentration may not be a good target for polymyxin B therapeutic drug monitoring

Bibliographic Details
Main Authors:	Yuhua Zhao, Huadong Chen, Zhenwei Yu
Format:	Article
Language:	English
Published:	BMC 2023-01-01
Series:	Critical Care
Online Access:	https://doi.org/10.1186/s13054-023-04326-8

Similar Items

Variability of Isavuconazole Trough Concentrations during Longitudinal Therapeutic Drug Monitoring
by: Léa Bolcato, et al.
Published: (2022-09-01)

Effectiveness, nephrotoxicity, and therapeutic drug monitoring of polymyxin B in nosocomial pneumonia among critically ill patients
by: Qinghua Ye, et al.
Published: (2022-05-01)

Correlation between the drug concentration of polymyxin B and polymyxin B‐associated acute kidney injury in critically ill patients: A prospective study
by: Ying Xu, et al.
Published: (2022-10-01)

Polymyxin B therapy based on therapeutic drug monitoring in carbapenem-resistant organisms sepsis: the PMB-CROS randomized clinical trial
by: Shaohua Liu, et al.
Published: (2023-06-01)

Polymyxin B sulphate
by: 982 SIRIM

Trough-only monitoring of serum vancomycin concentrations in neonates.
by: Shackley, F, et al.
Published: (1998)

Population Pharmacokinetics and Limited Sampling Strategy for Therapeutic Drug Monitoring of Polymyxin B in Chinese Patients With Multidrug-Resistant Gram-Negative Bacterial Infections
by: Peile Wang, et al.
Published: (2020-06-01)

The Difference Between Polymyxin B and Polymyxin E in Causing Skin Hyerpigmentation
by: Dongna Zou, et al.
Published: (2021-04-01)

Immunosuppressant therapeutic drug monitoring and trough level stabilisation after paediatric liver or kidney transplantation
by: Klara M. Posfay-Barbe, et al.
Published: (2019-12-01)

Reappraisal of therapeutic vancomycin trough concentrations with empirical dosing in neonatal infections
by: Tzung-Yi Lee, et al.
Published: (2023-03-01)

Synergistic Killing of Polymyxin B in Combination With the Antineoplastic Drug Mitotane Against Polymyxin-Susceptible and -Resistant Acinetobacter baumannii: A Metabolomic Study
by: Thien B. Tran, et al.
Published: (2018-04-01)

Polymyxin B combinations with FDA-approved non-antibiotic phenothiazine drugs targeting multi-drug resistance of Gram-negative pathogens
by: Maytham Hussein, et al.
Published: (2020-01-01)

Transcriptional responses of <it>Burkholderia cenocepacia </it>to polymyxin B in isogenic strains with diverse polymyxin B resistance phenotypes
by: Molinaro Antonio, et al.
Published: (2011-09-01)

Daily Clinical Dose (D) poorly predicts trough serum methadone concentration (C trough) in patients undergo methadone maintenance therapy with good adherence
by: Mohamed Nazar, Nor Ilyani, et al.
Published: (2014)

Polymyxin B-Induced Kidney Injury Assessment of a Novel Formulation of Polymyxin B (VRP-034) in Rats
by: Dilip Roy, et al.
Published: (2021-03-01)

Resveratrol enhances the antimicrobial effect of polymyxin B on Klebsiella pneumoniae and Escherichia coli isolates with polymyxin B resistance
by: Li Liu, et al.
Published: (2020-10-01)

Respiratory Muscle Paralysis Associated With Colistin, Polymyxin B, and Muscle Relaxants Drugs
by: Thein Myint MBBS, et al.
Published: (2016-03-01)

Corrigendum: Polymyxins and Their Potential Next Generation as Therapeutic Antibiotics
by: Martti Vaara, et al.
Published: (2019-10-01)

Polymyxins resistance: old antimicrobials, last therapeutic options
by: Raquel Girardello, et al.
Published: (2012-04-01)

Therapeutic drug monitoring of the teicoplanin trough level after the loading doses in patients receiving venoarterial extracorporeal membrane oxygenation
by: Guan-Jhou Chen, et al.
Published: (2020-06-01)

Flagella-dependent inhibition of biofilm formation by sub-inhibitory concentration of polymyxin B in Vibrio cholerae.
by: Sean Giacomucci, et al.
Published: (2019-01-01)

Sub-minimum inhibitory concentrations of colistin and polymyxin B promote Acinetobacter baumannii biofilm formation.
by: Yoshinori Sato, et al.
Published: (2018-01-01)

Comparison of Boric Acid and Combination Drug of Polymyxin, Neomycin and Hydrocortisone (polymyxin NH) in the Treatment of Acute Otitis Externa
by: Soroush Amani, et al.
Published: (2016-07-01)

Therapeutic Rationale for Endotoxin Removal with Polymyxin B Immobilized Fiber Column (PMX) for Septic Shock
by: Hisataka Shoji, et al.
Published: (2021-02-01)

Structure-Function Studies of Polymyxin B Lipononapeptides
by: Alejandra Gallardo-Godoy, et al.
Published: (2019-02-01)

Determining therapeutic trough ranges for linezolid
by: Abdullah Alsultan
Published: (2019-12-01)

Polymyxin B and fusidic acid, a novel potent synergistic combination against Klebsiella pneumoniae and Escherichia coli isolates with polymyxin B resistance
by: Shuying Chen, et al.
Published: (2023-10-01)

Feasibility of Extrapolating Randomly Taken Plasma Samples to Trough Levels for Therapeutic Drug Monitoring Purposes of Small Molecule Kinase Inhibitors
by: Ruben A. G. van Eerden, et al.
Published: (2021-02-01)

Multi-scale model of drug induced adaptive resistance of Gram-negative bacteria to polymyxin B.
by: Wojciech Krzyzanski, et al.
Published: (2017-01-01)

Synergistic Combination of Polymyxin B and Enrofloxacin Induced Metabolic Perturbations in Extensive Drug-Resistant Pseudomonas aeruginosa
by: Yu-Wei Lin, et al.
Published: (2019-10-01)

Intracellular and Plasma Trough Concentration and Pharmacogenetics of Telaprevir
by: Jessica Cusato, et al.
Published: (2015-05-01)

Design and Evaluation of Polygonal Trough Solar Concentrator
by: Yasser Yassin Khudair, et al.
Published: (2021-10-01)

Polymyxin B-induced skin and nail hyperpigmentation in an adult
by: Mahendra M Kura, et al.
Published: (2023-01-01)

Adverse effects of polymyxin B administration to healthy horses
by: Julia N. vanSpijk, et al.
Published: (2022-07-01)

Polymyxin B Nephrotoxicity: From Organ to Cell Damage.
by: Maria de Fátima Fernandes Vattimo, et al.
Published: (2016-01-01)

Enhancing the antibacterial activity of polymyxins using a nonantibiotic drug
by: Krishnamurthy M, et al.
Published: (2019-05-01)

Risk factors for polymyxin B-associated acute kidney injury
by: Kang Chang, et al.
Published: (2022-04-01)

Mid‐dosing interval concentration is important for polymyxin B exposure and acute kidney injury in critically ill patients
by: Jing Wang, et al.
Published: (2023-12-01)

Therapeutic Drug Monitoring of Isavuconazole: Serum Concentration Variability and Success Rates for Reaching Target in Comparison with Voriconazole
by: Malene Risum, et al.
Published: (2021-04-01)

Loading regimen required to rapidly achieve therapeutic trough plasma concentration of teicoplanin and evaluation of clinical features
by: Seki M, et al.
Published: (2012-11-01)